Since 2022, four GLP-1 drugs, including those indicated for weight loss, have been on FDA’s drug shortage list due to extraordinarily high patient demand. The shortage has, in turn, resulted in ...

Patients are increasingly exploring treatment options that align with their specific needs and experiences, and 503A ...

Discover how compounding pharmacies are transforming healthcare by creating tailor-made medications for patients with unique needs, offering critical alternatives when standard drugs fall short, and ...

Among the local drug compounding regulators for 50 states, Washington, DC, Guam, Puerto and the US Virgin Islands, many say they are working with and appreciate the help of the US Food and Drug ...

COLORADO SPRINGS — Maybe you’ve heard of someone taking GLP-1s, or you’ve seen celebrities like Serena Williams talk about taking them for weight loss. Over the past few years, it’s been sold to ...

The US Food and Drug Administration (FDA) late Friday issued revised versions of two final guidance documents explaining the use of bulk drug substances in compounding and clarifying that the agency ...

The Food and Drug Administration proposed excluding Novo Nordisk and Eli Lilly's weight-loss drugs from a key compounding ...

Compounded semaglutide, tirzepatide and liraglutide could be harder to come by starting this summer, if the U.S. Food and Drug Administration (FDA) goes through with its plan to remove the three ...

Add Yahoo as a preferred source to see more of our stories on Google. Many Americans have turned to compounding pharmacies to get popular weight-loss drugs due to lack of availability or expensive ...

By Bhanvi Satija and Chris Prentice LONDON/NEW YORK, May 21 (Reuters) - Lower prices for weight-loss pills from Novo Nordisk ...